About us

Gerald L. Brown, PhD
Director, Commercialization

As PREVENT's Director of Commercialization, Dr. Gerry Brown has significant input into the selection of promising vaccine technologies, and responsibility for the establishment of collaboration, co-development and partnership agreements enabling progression of selected projects along the commercialization path.

Intellectual property assessment and protection, technology transfer, industry liaison and regulatory activities all fall within his mandate.

He originally trained in cell biology, physiology & immunology and psychology, with post-graduate work in biochemistry and molecular biology.

Over the past 20 years he has developed a broad background in agricultural biology, agronomy, and the development and commercialization of new product opportunities.

He has worked with the Plant Cell & Molecular Group, and the Microbial Inoculants Division, of Allelix Crop Technologies, the Ag Biologicals Team within the Esso/Exxon environment, Agrium Biologicals, and was the Principal Research Scientist, and Innovation and Intellectual Property Manager – New Products for Agrium Inc.

Dr. Brown joined the Saskatchewan Research Council as Director of SRC's Business Development Branch, with responsibilities ranging from marketing and communications to new product development, technology mentoring, investment, licensing and commercialization activities. His involvement with SRC's activities included mining, mineral exploration, petroleum recovery, climate change, ground water, analytical services, small industry services, intelligent systems and alternative fuels technologies.

As Vice-President of the Agriculture & Biotechnology Division of SRC he was responsible for: i) Bova-Can Labs, a joint venture partnership with seven major cattle breed associations in Canada focusing on purebred certification, genomics and genetic diagnostics for livestock and companion animal breeds, ii) the Fermentation and BioProcessing Business Unit, a pilot plant facility providing bioprocessing and process development expertise and pilot plant production of veterinary and human vaccines and therapeutics, and microbial inoculants, and iii) GenServe Laboratories, a high-throughput sequencing genetics/genomics facility servicing animal, plant and microbial interests.

Dr. Brown currently sits on the Board of Genome Prairie and Ag-West Bio's Agriculture Biotechnology International Congress.

Phone: (306) 966-1506; Deprecated: Function split() is deprecated in /cwis/aliases/prevent-cecr/include/lib.inc on line 60 gerry.brown@usask.ca


Did you know?
image of E. coli bacteria

Escherichia coli (E. coli), is a bacterium commonly found in the lower intestine of warm-blooded animals. Most E. coli strains are harmless and are part of the normal beneficial flora of the gut, but some, such as serotype O157:H7, can cause serious food poisoning in humans. Ingestion of contaminated water or food is the usual causes of illness from E. coli.

BACKGROUNDER

Immunization:
Inoculation and Vaccination

Inoculation (also known as variolation) was introduced to the west by Lady Mary Wortley Montagu (1689-1762), who witnessed inoculation being
portrait of lady
practiced by physicians in Constantinople,[12] and was greatly impressed:[13] she had lost a brother to smallpox and bore facial scars from the disease herself. In 1718 she had the embassy surgeon inoculate her son, and in 1721, after returning to England, had her daughter inoculated[14]. In 1722 the Prince of Wales' daughters received inoculations[16].

The practice of inoculation slowly spread amongst the royal families of Europe, followed by general adoption amongst the rest of the population. Given the severe consequences of smallpox in Europe in the 18th century, many parents felt that the benefits outweighed the risks and so inoculated their children.[21] [22]

... more